COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,050 Articles (22,627 medRxiv, 8,423 bioRxiv)

Most recent first Previous |  Page 2685: Articles 26841-26850  | Next

Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports
Cohen, I. V., Makunts, T., Moumedjian, T., Issa, M., Abagyan, R.
10.1101/2020.05.19.20107227 — Posted: 2020-05-26
Ethnic and regional variation in hospital mortality from COVID-19 in Brazil
Baqui, P. O., Bica, I., Marra, V., Ercole, A., Van Der Schaar, M.
10.1101/2020.05.19.20107094 — Posted: 2020-05-26
Quantitative modeling and analysis show country-specific quarantine measures can circumvent COVID19 infection spread post lockdown
Sarma, U., Ghosh, B.
10.1101/2020.05.20.20107169 — Posted: 2020-05-26
Transmission of SARS-CoV-2 in Georgia, USA, 2020
Muniz-Rodriguez, K., Chowell, G., Schwind, J. S., Ford, R., Ofori, S. K., Ogwara, C. A., Davies, M. R., Jacobs, T., Cheung, C.-H., Cowan, L. T., Hansen, A. R., Fung, I. C.-H.
10.1101/2020.05.19.20107219 — Posted: 2020-05-26
Renin-angiotensin-aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID-19: a systematic review and meta-analysis
Ssentongo, A., Ssentongo, P., Heilbrunn, E. S., Lekoubou, A., Du, P., Liao, D., Oh, J. S., Chinchilli, V. M.
10.1101/2020.05.21.20107003 — Posted: 2020-05-26
The Outcome Impact of Early vs Late HFNC Oxygen Therapy in Elderly Patients with COVID-19 and ARDS
Deng, L., Lei, S., Jiang, F., Lubarsky, D. A., Zhang, L., Liu, D., Han, C., Zhou, D., Wang, Z., Sun, X., Zhang, Y., Cheung, C. W., Wang, S., Xia, Z.-y., Applegate, R. L., Liu, H., Tang, J., Xia, Z.
10.1101/2020.05.23.20111450 — Posted: 2020-05-26
Efficacy and Safety of Hydroxychloroquine and Chloroquine for COVID-19: A systematic review
Singh, S., Moore, T. J.
10.1101/2020.05.19.20106906 — Posted: 2020-05-26
Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial
Cavalcanti, A. B., Zampieri, F. G., Azevedo, L. C., Rosa, R. G., Avezum, A., Veiga, V. C., Lopes, R. D., Kawano-Dourado, L., Damiani, L. P., Pereira, A. J., Serpa Neto, A., Furtado, R., Tomazini, B., Bozza, F. A., Maia, I. S., Falavigna, M., Lisboa, T. C., Fonseca, H., Machado, F. R., Berwanger, O., COALITION COVID-19 Brazil I Investigators
10.1101/2020.05.19.20106997 — Posted: 2020-05-26
A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways
Lorenzo-Redondo, R., Nam, H. H., Roberts, S. C., Simons, L. M., Jennings, L. J., Qi, C., Achenbach, C. J., Hauser, A. R., Ison, M. G., Hultquist, J. F., Ozer, E. A.
10.1101/2020.05.19.20107144 — Posted: 2020-05-26 Discussion: Onsite
Strict Physical Distancing May Be More Efficient: A Mathematical Argument for Making Lockdowns Count
Bilinski, A., Fitzpatrick, M. C., Sheffield, S. R., Swartwood, N. A., Williamson, A., York, A.
10.1101/2020.05.19.20107045 — Posted: 2020-05-26 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).